Global CDMO, Recipharm, has signed a deal with a pharma company to support vaccine manufacturing from its facility in Kaysersberg, France.
The agreement was announced following a successful quality audit and will see the company aseptically pack single-use vaccines used to treat a severe infectious disease that affects both young children and infants.
The containers will be filled using Recipharm’s specialist blow-fill-seal (BFS) capabilities, creating products that are quick to distribute and simplifying administration for healthcare providers.
The company plans to recruit more than 30 members of staff between 2022 and 2026 as the product scales towards commercial production.
Yves Buelens, General Manager at Recipharm’s facility in Kaysersberg, said: “We are very proud to be supporting a big pharma partner in the delivery of a vital vaccine to the market.
This deal is indicative of Recipharm’s successful and ongoing product portfolio diversification. We’ve invested heavily into new capabilities that have built on our BFS expertise and as a result, strengthened our biotech offering. We are now in a position to welcome new biopharma projects to the Kaysersberg site.”
Located in the Alsace region of France, Kaysersberg is one of the company’s specialist sterile manufacturing facilities which had been previously dedicated to the exclusive production of sterile liquids for therapeutic areas, including eye care and ear drops. The company is investing $15.5m into its vaccine manufacturing offering at the site.
The facility has been inspected and approved by multiple regulatory agencies across the globe including ANSM (EU-GMP), FDA and Brazil’s ANVISA. It also holds several approvals for its environmental management systems and occupational health and safety management system.
